GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Cyclically Adjusted PS Ratio

Arbutus Biopharma (Arbutus Biopharma) Cyclically Adjusted PS Ratio : 10.11 (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Arbutus Biopharma's current share price is $2.73. Arbutus Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.27. Arbutus Biopharma's Cyclically Adjusted PS Ratio for today is 10.11.

The historical rank and industry rank for Arbutus Biopharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

ABUS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.02   Med: 5.21   Max: 16.21
Current: 10.03

During the past years, Arbutus Biopharma's highest Cyclically Adjusted PS Ratio was 16.21. The lowest was 1.02. And the median was 5.21.

ABUS's Cyclically Adjusted PS Ratio is ranked worse than
69.31% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs ABUS: 10.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arbutus Biopharma's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.013. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.27 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted PS Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.42 6.06 8.72 6.21 9.22

Arbutus Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.21 8.28 6.63 6.22 9.22

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PS Ratio falls into.



Arbutus Biopharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Arbutus Biopharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.73/0.27
=10.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Arbutus Biopharma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.013/129.4194*129.4194
=0.013

Current CPI (Dec. 2023) = 129.4194.

Arbutus Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.224 99.695 0.291
201406 0.082 100.560 0.106
201409 0.197 100.428 0.254
201412 0.195 99.070 0.255
201503 0.155 99.621 0.201
201506 0.063 100.684 0.081
201509 0.080 100.392 0.103
201512 0.217 99.792 0.281
201603 0.012 100.470 0.015
201606 0.006 101.688 0.008
201609 0.014 101.861 0.018
201612 -0.004 101.863 -0.005
201703 0.004 102.862 0.005
201706 0.019 103.349 0.024
201709 0.126 104.136 0.157
201712 0.046 104.011 0.057
201803 0.026 105.290 0.032
201806 0.022 106.317 0.027
201809 0.029 106.507 0.035
201812 0.030 105.998 0.037
201903 0.012 107.251 0.014
201906 0.011 108.070 0.013
201909 0.054 108.329 0.065
201912 0.027 108.420 0.032
202003 0.022 108.902 0.026
202006 0.022 108.767 0.026
202009 0.019 109.815 0.022
202012 0.028 109.897 0.033
202103 0.023 111.754 0.027
202106 0.024 114.631 0.027
202109 0.033 115.734 0.037
202112 0.024 117.630 0.026
202203 0.085 121.301 0.091
202206 0.096 125.017 0.099
202209 0.039 125.227 0.040
202212 0.040 125.222 0.041
202303 0.041 127.348 0.042
202306 0.028 128.729 0.028
202309 0.028 129.860 0.028
202312 0.013 129.419 0.013

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (NAS:ABUS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Arbutus Biopharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (Arbutus Biopharma) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Executives
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims officer: Chief Medical Officer 701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger officer: General Counsel and CCO 633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia officer: Chief Scientific Officer C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh officer: Chief Business Officer C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers director GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng director 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier director, officer: President and CEO C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard officer: Executive VP & General Counsel 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings officer: Chief Financial Officer C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio officer: Chief Development Officer C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8